Clinical Trials
8 trialsNCT05736419 2026-04-08
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04099966 2025-08-08
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
New York Medical College
Phase 2 Recruiting
NCT03333486 2025-07-04
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT03944447 2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2 Unknown
NCT01895361 2020-01-31
SUSTAIN
Reprixys Pharmaceutical Corporation
Phase 2 Completed
NCT01049854 2018-08-21
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
New York Medical College
Phase 2 Completed
NCT00236041 2014-05-09
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00236093 2014-05-09
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed